Stocksigma LogoStocksigma Logo

Syncom Formulations Reports Strong Q2 FY27 Results Driven by Pharmaceuticals Growth

Syncom Formulations reported a consolidated revenue from operations of ₹14,214.49 lakhs for Q2 ended 30th Sep'26, rising 16.78% YoY and 13.24% QoQ

Syncom Formulations Reports Strong Q2 FY27 Results Driven by Pharmaceuticals Growth

Syncom Formulations India Ltd · Financial Result · 13 Nov 2026, 10:29 pm

Syncom Formulations Reports Strong Q2 FY27 Results Driven by Pharmaceuticals Growth Syncom Formulations reported a consolidated revenue from operations of ₹14,214.49 lakhs for Q2 ended 30th Sep'26, rising 16.78% YoY and 13.24% QoQ. Consolidated net profit reached ₹2,665.32 lakhs, marking a 60.55% YoY and 7.27% QoQ growth. PBT climbed 63.49% YoY to ₹3,602.77 lakhs, primarily propelled by the core pharmaceuticals segment delivering ₹3,517.63 lakhs in profit. Restated basic and diluted EPS improved to ₹0.28 from ₹0.18 YoY. For H1 ended 30th Sep'26, consolidated revenue stood at ₹26,767.13 lakhs with net profit of ₹5,150.00 lakhs.

Original exchange filing (PDF)

More announcements from Syncom Formulations India Ltd

All Syncom Formulations India Ltd announcements